Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00697710 · ClinicalTrials.gov registry record · Phase 1
A Phase Ib/IIa, Double-Blind, Randomized Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of S-777469 in Subjects With Atopic Dermatitis
A Phase 1 study, sponsored by Shionogi.
- Completed
- Registry status
- Phase 1
- Development phase
- 37
- Enrollment target
NCT00697710 is a Phase 1 study that has completed, run by Shionogi. The registered enrollment target is 37 participants.
The verdict
NCT00697710, a Phase 1 study, has completed, sponsored by Shionogi.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 37 participants
- Enrollment target
Study Summary
The purpose of this randomized, double-blind, placebo-controlled, sequential-cohort, dose-escalation study was to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of S-777469, a CB2 cannabinoid receptor agonist, in subjects with mild to moderate atopic dermatitis.
Interventions
- DRUG Placebo
- DRUG 50 mg S-777469
- DRUG 200 mg S-777469
- DRUG 800 mg S-777469
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2007-07 |
| Est. Completion | 2008-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00697710
The ClinicalTrials.gov registry entry for NCT00697710 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Shionogi, which has 54 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT00697710 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00697710 about?
NCT00697710 is a clinical study titled "A Phase Ib/IIa, Double-Blind, Randomized Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of S-777469 in Subjects With Atopic Dermatitis". The purpose of this randomized, double-blind, placebo-controlled, sequential-cohort, dose-escalation study was to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of S-777469, a CB2 cannabinoid receptor agonist, in subjects with mild to moderate atopic dermatitis.
What is the current status of trial NCT00697710?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 37 participants. The study started on 2007-07. Estimated completion is 2008-09.
What interventions are being tested in trial NCT00697710?
The interventions under investigation include: Placebo (DRUG), 50 mg S-777469 (DRUG), 200 mg S-777469 (DRUG), 800 mg S-777469 (DRUG).
Who is sponsoring clinical trial NCT00697710?
This trial is sponsored by Shionogi, which has 54 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.